• Exploring use of Altamira’s RNA nanoparticles in conjunction with circular RNA payloads
• Project collaboration partner will have option to negotiate licensing agreement

Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, announced that it has entered into a collaboration agreement with an undisclosed company to evaluate the potential use of Altamira’s proprietary CycloPhore™ platform for the delivery of circular RNA payloads under development by the partner company.

Under the terms of the agreement, Altamira and its collaboration partner intend to test in vitro and in vivo the use of CycloPhore nanoparticles. The partner will, under certain conditions, have the option to negotiate with Altamira a license agreement to develop and commercialize circRNA nanoparticles with their proprietary RNA payload.   

“We are very excited to enter in this first collaboration to explore the utility of our CycloPhore platform”, commented Covadonga Pañeda, PhD, Altamira’s Chief Operating Officer. “CycloPhore was launched only recently specifically for delivery of circular RNA, which has been emerging as a highly promising approach for RNA drug development. For instance, circular mRNA could allow for lower dosing and less frequent administrations than linear mRNA. We look forward to working with our new partner who has strong expertise in circular RNA and the ambition to develop truly life changing therapeutics.”